Which is better, retatrutide or survodutide?
On weight, retatrutide wins clearly: its phase 2 placebo adjusted loss (about 22 percentage points at 12 mg) is roughly three times survodutide's phase 3 placebo adjusted loss (about 7 to 8 points), although the trials differ in phase, length, and population. Both hold the human_rct grade and the same not_eligible regulatory status, and survodutide has stronger liver histology data. No trial has compared them directly and neither has reported cardiovascular outcomes. [1] [5] [6] [10]
How do retatrutide and survodutide compare?
| Dimension | RetatrutideFavored | Survodutide |
|---|---|---|
| Mechanism [1] [5] | Triple agonist of the GIP, GLP-1, and glucagon receptors. | Dual agonist of the glucagon and GLP-1 receptors (no GIP activity). |
| Note: Both use glucagon receptor activity to raise energy expenditure and liver fat oxidation. | ||
| Best weight loss evidence [1] [4] [5] | Phase 2 (338 adults, 48 weeks): 8.7%, 17.1%, 22.8%, and 24.2% at 1, 4, 8, and 12 mg versus 2.1% on placebo. | Phase 3 SYNCHRONIZE-1 (725 adults, 76 weeks): 12.2% at 3.6 mg and 13.0% at 6.0 mg versus 5.4% on placebo. |
| Note: Cross-trial comparison only; phase 3 obesity results for retatrutide (TRIUMPH) are still being reported. | ||
| Liver disease evidence [1] [6] | No dedicated liver histology trial in the record; liver fat reduction is a secondary rationale for glucagon activity. | Phase 2 MASH trial (293 adults, 48 weeks): MASH improvement without worsening fibrosis in 47%, 62%, and 43% at 2.4, 4.8, and 6.0 mg versus 14% on placebo. |
| Type 2 diabetes evidence [2] [3] [5] | Phase 2 (281 adults, 36 weeks) against placebo and dulaglutide, and phase 3 TRANSCEND-T2D-1 (537 adults, 40 weeks) with significant HbA1c and weight improvement. | SYNCHRONIZE-1 excluded people with diabetes; the record has no published diabetes efficacy trial. |
| Side effects [1] [5] [7] | Dose related nausea, diarrhea, vomiting, and constipation; heart rate increase greater than GLP-1 only drugs; skin sensitivity and dysesthesia reported in phase 2. | Gastrointestinal symptoms in 80.9% (3.6 mg) and 89.7% (6.0 mg) versus 47.9% on placebo in SYNCHRONIZE-1; decreased appetite drove withdrawals during escalation in phase 1. |
| Trial doses [1] [3] [5] [6] | Once weekly, escalated every 4 weeks to 1, 4, 8, or 12 mg (phase 2 obesity); 4, 9, or 12 mg in phase 3 diabetes. | Once weekly, escalated over a prolonged period to 3.6 or 6.0 mg (SYNCHRONIZE-1); 2.4 to 6.0 mg in the MASH trial. |
| Note: Trial regimens only; no approved label exists for either. | ||
| Regulatory and access status [4] [8] [10] [11] | Not approved by FDA or any other regulator; not on the 503A bulks list, so it cannot be compounded. Phase 3 TRIUMPH program ongoing. | Not approved by FDA or any other regulator; not on the 503A bulks list, so it cannot be compounded. Phase 3 SYNCHRONIZE program, including a cardiovascular outcomes trial, ongoing. |
| Note: Both are prohibited in sport under WADA section S0. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Retatrutide | Survodutide |
|---|---|---|
| Class | Investigational triple agonist of the GIP, GLP-1, and glucagon receptors (single acylated peptide, once weekly) | Investigational dual agonist of the glucagon and GLP-1 receptors (acylated peptide, once weekly) |
| What it is | Investigational triple agonist, nicknamed reta or GLP-3, with 24.2% weight loss at 48 weeks in phase 2 and 28.3% in a phase 3 topline; not FDA approved. | Investigational glucagon/GLP-1 dual agonist: 13% weight loss at 76 weeks in phase 3 and strong liver (MASH) data, but not FDA approved. |
| Evidence | Evidence: Human RCT evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: Not eligible for compounding | Regulatory: Not eligible for compounding |
| Compounding | Not FDA approved and not approved by any other regulator as of the last verification date. Because retatrutide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded by 503A pharmacies or 503B outsourcing facilities. FDA has warned that unapproved GLP-1 class products sold online, including investigational molecules, are not evaluated for safety, quality, or dose. Any product sold as retatrutide outside a clinical trial is unlawful for human use. | Not FDA approved and not approved by any other regulator as of the last verification date. Because survodutide is not a component of an approved drug, has no USP monograph, and is not on the 503A bulks list, it cannot lawfully be compounded by 503A pharmacies or 503B outsourcing facilities. Any product sold as survodutide outside a clinical trial is an unapproved drug that has not been evaluated for identity, purity, or dose. |
| WADA | WADA: WADA prohibited | WADA: WADA prohibited |
| Routes | Subcutaneous injection once weekly (clinical trials only) | Subcutaneous injection once weekly (clinical trials only) |
| Typical cost | Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Last verified |
Has retatrutide been tested directly against survodutide?
No published trial has compared retatrutide and survodutide directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do retatrutide and survodutide cost?
| Dimension | Retatrutide | Survodutide |
|---|---|---|
| Typical cost | Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | Not available through licensed channels. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Price detail | Retatrutide price by channel | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Frequently asked questions
Which causes more weight loss, retatrutide or survodutide?
Retatrutide, based on published trials: 24.2% at 48 weeks on 12 mg in phase 2 versus 12.2% to 13.0% at 76 weeks for survodutide in phase 3. The trials are not directly comparable and no head-to-head trial exists. [1] [5]
Why is survodutide being studied for liver disease?
Glucagon receptor activation increases liver fat oxidation. In a 48 week phase 2 trial in biopsy confirmed MASH, 43% to 62% of treated participants improved without worsening fibrosis versus 14% on placebo. [6]
Can I get either one legally?
Only in a registered clinical trial. Neither is FDA approved, neither is a component of an approved drug or on the 503A bulks list, so compounding pharmacies cannot lawfully make them, and products sold as research chemicals are not lawful for human use. [9] [10]
Are they allowed in sport?
No. Both are prohibited at all times under WADA section S0, which covers substances not approved for human therapeutic use. [11]
What are the main side effects?
Mostly gastrointestinal for both. Survodutide caused gastrointestinal symptoms in 80.9% to 89.7% of participants versus 47.9% on placebo in SYNCHRONIZE-1. Retatrutide raised heart rate more than GLP-1 only drugs and caused skin sensitivity in some phase 2 participants. [1] [5]
Conditions studied
From the blog
- Retatrutide: where the phase 3 program stands
Five phase 3 readouts, one peer-reviewed paper, and no approval yet. What the retatrutide trials have shown, what is still pending, and why no one can lawfully sell it today.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023PubMed 37366315, 2023
- [2]Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial. Lancet 2023PubMed 37385280, 2023
- [3]Efficacy and safety of retatrutide in people with type 2 diabetes (TRANSCEND-T2D-1): a phase 3 trial. Lancet 2026PubMed 42250575, 2026
- [4]Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab 2026PubMed 41090431, 2026
- [5]le Roux CW et al. Survodutide once weekly for the treatment of adults with obesity. N Engl J Med 2026 (SYNCHRONIZE-1)PubMed 42253238, 2026
- [6]Sanyal AJ et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med 2024PubMed 38847460, 2024
- [7]A randomized phase 1 study of BI 456906 in healthy Japanese men with overweight/obesity. Diabetes Obes Metab 2023PubMed 36974349, 2023
- [8]Wharton S et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and -2). Obesity 2025PubMed 39495965, 2025
- [9]FDA: concerns with unapproved GLP-1 drugs used for weight lossFDA
- [10]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA
- [11]WADA Prohibited List, section S0 non-approved substancesWADA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). Retatrutide vs survodutide: evidence, cost, and legality. https://peptideagent.ai/compare/retatrutide-vs-survodutide- HTML link
<a href="https://peptideagent.ai/compare/retatrutide-vs-survodutide">Retatrutide vs survodutide: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.